Phenomenon of nitrate tolerance

https://doi.org/10.1016/0002-8703(94)90020-5Get rights and content

Abstract

The phenomenon of nitrate tolerance has now been appreciated for almost a century, and our understanding of this process has greatly improved during the past 20 years. Therapeutic nitrates are now recognized as exogenous sources of nitric oxide (or nitrosothiols), which appears to be a primary mediator of natural vasodilatation. Nitrates have been clearly shown to have vasodilatory and antiplatelet effects, both of which diminish during continuous exposure. Nitrate tolerance has been documented with most nitrate preparations when the patient is given continuous nitrate therapy. Tolerance to nitrates may occur in any patient, regardless of underlying illness, medication dose, or serum concentration of NTG. The cause of this phenomenon is multifactorial; there appear to be both cellular and systemic processes involved. To date, no adjuvant pharmacologic intervention has conclusively demonstrated benefit in preventing, abating, or reversing nitrate tolerance. Interruption of nitrate exposure for as little as 8 to 12 hours does appear to be the best means of preventing or reversing tolerance. Nevertheless, some patients with objective tolerance continue to experience relief of symptoms. In addition, despite laboratory-documented cross-tolerance, patients receiving continuous nitrate therapy at usual clinical doses may continue to benefit from the hemodynamic and antianginal effects of SL NTG. Hence, nitrate tolerance is a real entity, but the clinical importance of this phenomenon remains controversial. Finally, further investigation will need to address quality-of-life issues and perhaps assess relief of ischemia by other means.

References (98)

  • JO Parker et al.

    Transdermal nitroglycerin in angina pectoris

    Am J Cardiol

    (1984)
  • D Manyari et al.

    Isosorbide dinitrate and glyceryl trinitrate: demonstration of cross tolerance in the capacitance vessels

    Am J Cardiol

    (1985)
  • P Varriale et al.

    Hemodynamic resistance to intravenous nitroglycerin in severe congestive heart failure and restored response after diuresis

    Am J Cardiol

    (1991)
  • CA Gruetter et al.

    Dissociation of cysteine and glutathione levels for nitroglycerin-induced relaxation

    Eur J Pharmacol

    (1985)
  • N Dakak et al.

    Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease

    Am J Cardiol

    (1990)
  • H Demots et al.

    intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina

    J Am Coll Cardiol

    (1989)
  • PA de Milliano et al.

    Long term efficacy of continuous and intermittent use of transdermal nitroglycerin in stable angina pectoris

    Am J Cardiol

    (1991)
  • E Rossetti et al.

    Transdermal nitroglycerin reduces the frequency of angina attacks but fails to prevent silent ischemia

    J Am Coll Cardiol

    (1993)
  • S Silber et al.

    Induction and circumvention of nitrate tolerance applying different dosing intervals

    Am J Med

    (1987)
  • WE Shell et al.

    Dissociation of exercise tolerance and total myocardial ischemic burden in chronic stable angina

    Am J Cardiol

    (1990)
  • Oral anti-anginal nitrates should be indicated only for single, not chronic, use in absence of long-term data, FDA cardio-renal adyisory CMTE concludes

    FDA Reports [The Pink Sheet]

    (7 June, 1993)
  • W Murrel

    Nitroglycerin as a remedy for angina pectoris

    Lancet

    (1879)
  • GE Ebright

    The effects of nitroglycerin on those engaged in its manufacture

    JAMA

    (1914)
  • AM Schwartz

    The cause, relief and prevention of headaches rising from contact with dynamite

    N Engl J Med

    (1946)
  • DD Stewart

    Remarkable tolerance to nitroglycerin

    Philadelphia Polyclinic

    (1888)
  • LA Crandall et al.

    The rate of elimination of glyceryl trinitrate from the blood stream after intravenous administration in dogs

    J Pharmacol Exp Ther

    (1929)
  • HB Myers et al.

    Nitrate toleration

    J Pharmacol Exp Ther

    (1929)
  • CK Friedberg

    Acute coronary occlusion and myocardial infarction

  • N Reichek et al.

    Sustained effects of nitroglycerin ointment in patients with angina pectoris

    Circulation

    (1974)
  • MG Bogaert et al.

    Tolerance towards glyceryl trinitrate (trinitrin) in dogs

    Arch Int Pharmacodyn

    (1968)
  • MG Bogaert

    Tolerance towards glyceryl trinitrate (trinitrin) in rabbits

    Arch Int Pharmacodyn

    (1968)
  • P Needleman

    Tolerance to the vascular effects of glyceryl trinitrate

    J Pharmacol Exp Ther

    (1970)
  • AG Herman et al.

    Organic nitrates: tolerance at the level of the vascular smooth muscle

    Arch Int Pharmacodyn

    (1971)
  • DG Clark et al.

    Metabolism of ethylene glycol dinitrate (ethylene dinitrate) in the rat following repeated administration

    Br J Ind Med

    (1969)
  • F Murad

    Cyclic guanosine monophosphate as a mediator of vasodilation

    J Clin Invest

    (1986)
  • S Katsuki et al.

    Stimulation of gunaylate cyclase activity by sodium nitroprusside, nitroglycerin, and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine

    J Cyclic Nucleotide Res

    (1977)
  • F Derubertis et al.

    Calcium-independent modulation of cyclic GMP and activation of guanylate cyclase by nitrosamines

    Science

    (1976)
  • J Diamond et al.

    Effects of stimulant and relaxant drugs on tension and cyclic nucleotide levels in canine femoral artery

    Mol Pharmacol

    (1976)
  • CA Gruetter et al.

    Relationship between cyclic guanosine 3′,5′-monophosphate formation and relaxation of coronary arterial smooth muscle by glyceryl trinitrate, nitroprusside, nitrite and nitric acid: effects of methylene blue and methemoglobin

    J Pharmacol Exp Ther

    (1981)
  • C Mittal et al.

    Characterization of protein inhibitors of guanasine cyclase activation from rat and bovine lung

    J Biol Chem

    (1978)
  • L Ignarro et al.

    Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates

    J Pharmacol Exp Ther

    (1981)
  • R Rapoport et al.

    Endothelium dependent relaxation in rat aorta may be mediated through cGMP dependent protein phosphorylation

    Nature

    (1983)
  • RR Fiscus et al.

    Endothelium dependent and nitrovasodilator induced activation of cyclic GMP-dependent protein kinase in rat aorta

    J Cyclic Nucleotide Prot Phosph Res

    (1983/4)
  • R Rapoport et al.

    Endothelium dependent and nitrovasodilator-induced relaxation of vascular smooth muscle: role of cyclic GMP

    J Cyclic Nucleotide Prot Phosph Res

    (1983)
  • RM Rapoport et al.

    Endothelium dependent vasodilator and nitrovasodilator induced relaxation may be mediated through cyclic GMP formation and cGMP dependent protein phosphorylation

    Trans Assoc Am Phys

    (1983)
  • B Trimarco et al.

    Late phase of nitroglycerin-induced coronary vasodilation blunted by inhibition of prostaglandin systems

    Circulation

    (1985)
  • S Kobayashi et al.

    Cytosolic-free calcium transients in cultured vascular smooth muscle cells: microflurometric measurements

    Science

    (1985)
  • R Furchgott et al.

    The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine

    Nature

    (1980)
  • Cited by (73)

    • Tailored therapy for aggressive dilatation of systemic veins and arteries may result in improved long-term Fontan circulation

      2015, Journal of Thoracic and Cardiovascular Surgery
      Citation Excerpt :

      Several important issues deserve further discussion to establish the efficacy and safety of the proposed tailored therapy. Adult patients on nitrates, including isosorbide dinitrate, may develop drug tolerance.8 Although we did not observe this effect in the children who underwent Fontan surgery in this study, after at least 1 year of administration, further studies with longer follow-up data are needed to address this issue.

    • Nitrate therapy for heart failure. Benefits and strategies to overcome tolerance

      2013, JACC: Heart Failure
      Citation Excerpt :

      Interestingly, plasma nitrate concentrations are higher with short-term than with long-term therapy, even at the same dose (37,40). This combination of decreased functionality and increased inactivity leads to reversal of the physiologic benefits of nitrate and to the development of tolerance (21,26,37). Several studies have assessed the hemodynamic tolerance to nitrates in patients with HF (21,22,25,26,41–44).

    View all citing articles on Scopus
    View full text